R75761, a lead compound for the development of antiviral drugs in late stage poliomyelitis eradication strategies and beyond

被引：6

作者：

Thys, Bert ^{[1
]}

De Palma, Armando M. ^{[2
]}

Neyts, Johan ^{[2
]}

Andries, Koen ^{[3
]}

Vrijsen, Raf ^{[1
]}

Rombaut, Bart ^{[1
]}

机构：

[1] Vrije Univ Brussel, Dept Pharmaceut Biotechnol & Mol Biol, B-1090 Brussels, Belgium

[2] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium

[3] Johnson & Johnson Pharmaceut Res & Dev, B-2340 Beerse, Belgium

来源：

ANTIVIRAL RESEARCH | 2008年 / 78卷 / 03期

关键词：

anti-poliovirus compound; polio eradication; pyridazinamine analogue; picornavirus; poliovirus;

D O I：

10.1016/j.antiviral.2008.01.002

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

In this study the antiviral activity of a panel of 18 out of 240 pyridazinamine analogues was evaluated against the Sabin strains of the three poliovirus types. We found one compound, R75761 which had a comparable 50% effective concentration (EC(50)) value against all three poliovirus Sabin strains. Virus multiplication was reduced by 10(4.0)-fold, 10(6.2)-fold and 10(6.6)-fold for poliovirus type 1, type 2 and type 3, respectively. R75761 could be considered as a lead compound for development of anti-poliovirus drugs to be used during the late stage of poliovirus eradication and beyond. (C) 2008 Elsevier B.V. All rights reserved.

引用

页码：278 / 281

页数：4